Franklin Biotechnology Discovery Fund Class A (FBDIX)

NASDAQ · Mutual Fund · Delayed Price · Currency is USD
121.06
+0.93 (0.77%)
Jul 10, 2025, 4:00 PM EDT
-14.17%
Fund Assets 676.00M
Expense Ratio 1.05%
Min. Investment $1,000
Turnover 35.87%
Dividend (ttm) 11.76
Dividend Yield 9.25%
Dividend Growth n/a
Payout Frequency n/a
Ex-Dividend Date Dec 20, 2024
Previous Close 120.13
YTD Return 0.54%
1-Year Return 1.23%
5-Year Return -6.43%
52-Week Low 99.30
52-Week High 152.68
Beta (5Y) 0.56
Holdings 88
Inception Date Sep 15, 1997

About FBDIX

Franklin Biotechnology Discovery Fund Class A is an open-end mutual fund focused on **capital appreciation through investments in the biotechnology sector**. Its core mandate is to allocate at least 80% of its net assets to equity securities of biotechnology companies and discovery research firms, which may include organizations involved in drug discovery, genomics, genetic engineering, and gene therapy. The fund's holdings span both established large-cap biotechnology firms and emerging companies, offering balanced exposure across different stages of the industry lifecycle. Notable positions typically include leaders in healthcare innovation, such as Amgen, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals. The fund’s investment universe also extends to companies involved in applying biotechnology advances to healthcare, pharmaceuticals, and, to a lesser extent, agriculture. As a non-diversified fund, it generally holds a concentrated portfolio, often allocating a substantial portion of assets to its top ten holdings. With a specialization in a fast-evolving and research-driven field, Franklin Biotechnology Discovery Fund Class A plays a distinct role in the market by channeling capital to firms at the forefront of medical and scientific progress, appealing to investors seeking targeted exposure to the biotechnology sector.

Fund Family Franklin Templeton Investments
Category Health
Stock Exchange NASDAQ
Ticker Symbol FBDIX
Share Class Class A
Index NASDAQ Biotechnology CR

Performance

FBDIX had a total return of 1.23% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.49%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol Share Class Expense Ratio
FRBRX Class R6 0.69%
FTDZX Advisor Class 0.80%
FBTDX Class C 1.80%

Top 10 Holdings

49.47% of assets
Name Symbol Weight
Gilead Sciences, Inc. GILD 8.17%
Amgen Inc. AMGN 7.64%
Vertex Pharmaceuticals Incorporated VRTX 7.25%
Ascendis Pharma A/S ASND 4.89%
Regeneron Pharmaceuticals, Inc. REGN 4.34%
argenx SE ARGX 3.80%
Jazz Pharmaceuticals plc JAZZ 3.79%
Merus N.V. MRUS 3.52%
PTC Therapeutics, Inc. PTCT 3.16%
Neurocrine Biosciences, Inc. NBIX 2.91%
View More Holdings

Dividend History

Ex-Dividend Amount Pay Date
Dec 20, 2024 $11.7607 Dec 20, 2024
Dec 20, 2022 $0.1411 Dec 20, 2022
Dec 15, 2021 $17.6831 Dec 15, 2021
Dec 15, 2020 $10.3921 Dec 15, 2020
Dec 16, 2019 $14.1643 Dec 18, 2019
Dec 17, 2018 $4.5496 Dec 19, 2018
Full Dividend History